Welcome to our dedicated page for Acurx Pharmaceuticals SEC filings (Ticker: ACXP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clinical-stage biotech disclosures can feel like reading a dense lab notebook—especially when Acurx Pharmaceuticals’ 10-K packs trial protocols, patent cliffs and cash-runway math into one document. Missing a single paragraph could mean overlooking an FDA milestone or dilution risk.
Stock Titan’s AI turns those pages into plain-English answers. Whether you need the Acurx Pharmaceuticals quarterly earnings report 10-Q filing for R&D burn analysis or want Acurx Pharmaceuticals insider trading Form 4 transactions before pivotal data, our platform highlights exactly where the numbers live. Real-time EDGAR feeds deliver every 8-K material event, while AI summaries flag why it matters—so you can move from document download to decision in minutes.
Here’s what you’ll uncover without digging through footnotes:
- Cash runway projections and Phase 3 spend straight from the latest 10-Q
- Executive stock moves via Acurx Pharmaceuticals Form 4 insider transactions real-time
- Compensation strategy inside the Acurx Pharmaceuticals proxy statement executive compensation
- Pivotal trial readouts disclosed through 8-K material events explained
- Risk-factor trends tracked across each Acurx Pharmaceuticals annual report 10-K simplified
Use the platform to compare quarter-over-quarter spending, monitor insider buying, and understand drug-development timelines—all with AI-powered clarity. No more scanning hundreds of pages; get understanding Acurx Pharmaceuticals SEC documents with AI and make faster, well-informed calls.
Acurx Pharmaceuticals, Inc. (ACXP) filed a Form D announcing a completed Rule 506(b) private placement of warrants. The filing reports an aggregate offering amount of $3,978,664, equivalent to the combined exercise prices of the inducement warrants issued to investors and the placement-agent warrants issued to H.C. Wainwright & Co. The entire amount has been sold, leaving $0 remaining, and the first sale occurred on 17 June 2025. Only one accredited investor participated, and the minimum investment was set at $0.
The securities offered were (i) warrants or other rights to acquire common stock and (ii) the common stock underlying those warrants. The offering is not related to a business combination and is expected to last less than one year.
Placement-agent compensation totaled $186,708 in cash (≈4.7% of the offering) plus warrants to purchase 266,726 shares at $0.75 per share. No finder’s fees were paid. The issuer declined to disclose its revenue range and claims no investment-company status.
Key investor takeaways:
- ACXP has secured incremental capital potential through warrant funding, although cash is only realized upon future exercise.
- The new warrants add dilution risk; exact share count of inducement warrants was not disclosed.
- Use-of-proceeds details were not provided in the excerpt.
Acurx Pharmaceuticals, Inc. (ACXP) filed an 8-K announcing a warrant-inducement transaction dated 17 June 2025.
Key cash component: a single holder exercised 4,445,435 existing Series A-D warrants at a reduced price of $0.60 per share, delivering ~$2.67 million gross / ~$2.3 million net cash to Acurx after a 7% placement fee and expenses.
New equity overhang: In exchange for the price reduction, Acurx granted the same holder
- Series G-1 warrants: 6,223,609 shares, exercisable immediately, $0.425 strike, 5-year term.
- Series G-2 warrants: 2,667,261 shares, exercisable post-stockholder approval, $0.425 strike, 5-year term from approval.
Potential dilution: including the exercised shares, up to ~13.6 million shares (4.45 M issued + 9.16 M new warrants) could enter the float, subject to ownership caps (4.99%/9.99%) and future exercise decisions.
Timing & registration: Closing targeted for 20 June 2025. Acurx must file a resale registration statement for the New Warrant Shares within 30 days and seek effectiveness within 60 days. For 45 days, the company is restricted from issuing additional equity and, for 90 days, from variable-rate financings (with limited exceptions).
Use of proceeds: general corporate and working-capital purposes.
Other terms: New warrants allow cashless exercise if resale registration is unavailable, include customary anti-dilution adjustments, lack an exchange listing, and contain standard fundamental-transaction protections.
Investor takeaway: The deal supplies modest near-term liquidity but meaningfully expands future share supply at sub-$1 strike prices, creating dilution risk while limiting additional near-term equity issuance.
FAQ
What is the current stock price of Acurx Pharmaceuticals (ACXP)?
What is the market cap of Acurx Pharmaceuticals (ACXP)?
What is Acurx Pharmaceuticals’ core focus?
How does Acurx differentiate its antibiotics from traditional treatments?
What types of infections are targeted by Acurx’s pipeline?
What is ibezapolstat and why is it significant?
What stage is Acurx’s clinical development currently in?
How does Acurx ensure the preservation of the gut microbiome?
Which regulatory bodies are involved in reviewing Acurx’s developments?
How does Acurx’s technology contribute to combating antibiotic resistance?
